RGNX has been in the news 600% more than usual
Feb 27, 2026, 7:33 AM
-11.25%
What does RGNX do
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
RGNX has been in the news recently: Levi & Korsinsky, LLP, along with other law firms, is filing class action lawsuits against REGENXBIO, Inc. for alleged securities fraud related to misleading statements about the RGX-111 product, impacting investors who purchased shares between February 9, 2022, and January 27, 2026. The lawsuits have arisen after a significant 17.8% drop in REGENXBIO's stock price, with a class action deadline set for April 14, 2026.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.